Frank Stegelmann
- Molecular Biology
- Hematology top 5%
- Genetics top 5%
- Rheumatology top 10%
- Infectious Diseases
- Co-authors
- Konstanze DöhnerSteffen StengerRobert L. ModlinNicholas C.P. CrossJoannah ScoreThomas ErnstNils WinkelmannClaire Hidalgo-Curtis
- Topics
- Chronic Myeloid Leukemia Treatments (27 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers)Acute Myeloid Leukemia Research (14 papers)
- Cited by
- GeneticsHematologyRheumatology
- Partner nations
- GermanyUnited KingdomItaly
In The Last Decade
Frank Stegelmann
33 papers receiving 613 citations
Peers
Comparison fields: 5 of 55
- Molecular Biology 318
- Hematology 301
- Genetics 300
- Rheumatology 132
- Infectious Diseases 98
Countries citing papers authored by Frank Stegelmann
This map shows the geographic impact of Frank Stegelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Stegelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Stegelmann more than expected).
Fields of papers citing papers by Frank Stegelmann
This network shows the impact of papers produced by Frank Stegelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Stegelmann. The network helps show where Frank Stegelmann may publish in the future.
Co-authorship network of co-authors of Frank Stegelmann
This figure shows the co-authorship network connecting the top 25 collaborators of Frank Stegelmann. A scholar is included among the top collaborators of Frank Stegelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Stegelmann. Frank Stegelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | 5 | |
| 5 | 1 | |
| 6 | 7 | |
| 7 | 9 | |
| 8 | 33 | |
| 9 | 7 | |
| 10 | 3 | |
| 11 | COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) | 2 |
| 12 | 14 | |
| 13 | 8 | |
| 14 | 49 | |
| 15 | 68 | |
| 16 | 125 | |
| 17 | 17 | |
| 18 | 35 | |
| 19 | 0 | |
| 20 | 74 |
About Frank Stegelmann
Frank Stegelmann is a scholar working on Genetics, Hematology and Rheumatology, having authored 37 papers that have together received 619 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers) and Acute Myeloid Leukemia Research (14 papers). The work is most often cited by research in Genetics (300 citations), Hematology (301 citations) and Rheumatology (132 citations). Frank Stegelmann has collaborated with scholars based in Germany, United Kingdom and Italy. Frequent co-authors include Konstanze Döhner, Steffen Stenger, Robert L. Modlin, Nicholas C.P. Cross, Joannah Score, Thomas Ernst, Nils Winkelmann, Claire Hidalgo-Curtis, Amy V. Jones and Daniel Ward. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.